What happened
Samsung Biologics updated the disclosed terms of a subsidiary's acquisition of Human Genome Sciences Inc., now worth US$347M.
For context, this deal is worth about 3.0% of the company's consolidated total assets.
| Target | Human Genome Sciences Inc. |
|---|---|
| Deal value | US$347M |
| vs. company assets | 3.0% |
| Filed | 2026-03-31, [Amended] Decision to acquire shares/equity in another company (voluntary) (subsidiary) |
| Source | DART rcept 20260331803716 → open original filing |
Source: DART. Information only, not investment advice.